Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for CorMedix (CRMD) over the last 11 years, with Sep 2025 value amounting to $109.1 million.

  • CorMedix's Accumulated Expenses rose 542.71% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year increase of 542.71%. This contributed to the annual value of $32.0 million for FY2024, which is N/A change from last year.
  • CorMedix's Accumulated Expenses amounted to $109.1 million in Q3 2025, which was up 324.18% from $25.7 million recorded in Q2 2025.
  • CorMedix's 5-year Accumulated Expenses high stood at $109.1 million for Q3 2025, and its period low was $1.4 million during Q1 2021.
  • For the 3-year period, CorMedix's Accumulated Expenses averaged around $24.3 million, with its median value being $12.3 million (2024).
  • Per our database at Business Quant, CorMedix's Accumulated Expenses tumbled by 67.87% in 2021 and then skyrocketed by 542.71% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Accumulated Expenses stood at $3.0 million in 2021, then spiked by 31.84% to $4.0 million in 2022, then skyrocketed by 62.43% to $5.1 million in 2023, then soared by 230.34% to $32.0 million in 2024, then spiked by 542.71% to $109.1 million in 2025.
  • Its Accumulated Expenses stands at $109.1 million for Q3 2025, versus $25.7 million for Q2 2025 and $32.3 million for Q1 2025.